Comparative Effectiveness of Psychosocial Interventions on Family Function and Resilience for Cancer Caregivers: A Systematic Review With Pairwise and Network Meta-analysis.

Cancer NursMar 4, 2025 (epub)

Jiang-Yan Song, Min Liu, Miao Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and pairwise and network meta-analysis assessed psychosocial interventions for family function and resilience among caregivers of people with cancer, using randomized controlled trial data. It included 12 studies with 1162 participants. In pairwise analysis, interventions were associated with improved family function (SMD, 1.34; 95% CI, 0.16-2.52). Network analysis also found improvements with family interaction approaches and psychoeducation. Neither analysis supported a positive effect on caregiver resilience.

Key findings

  • Across interventions, pairwise meta-analysis found improved family function (SMD, 1.34; 95% CI, 0.16-2.52).
  • Network analysis found improved family function with family interaction approaches (SMD, 0.69; 95% CI, 0.22-1.15).
  • Psychoeducation improved family function in network analysis (SMD, 0.66; 95% CI, 0.24-1.08).
  • Neither pairwise nor network meta-analysis found evidence of improved caregiver resilience.

Why it matters

Family function is a relevant outcome in cancer caregiving, and the findings suggest that psychosocial support may help strengthen it. The absence of demonstrated resilience benefits is also important: effects should not be assumed to extend across different caregiver outcomes. The review therefore highlights the value of considering family relationships and resources while recognising uncertainty about which outcomes interventions can improve.

What to keep in mind

The review included 12 studies, and the confidence interval for the overall family-function estimate was wide, indicating uncertainty in the effect estimate.

Source

Published in Cancer Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.